Sage Therapeutics Reports Phase 2 Huntington's Data
Portfolio Pulse from Dylan Berman
Sage Therapeutics (NASDAQ:SAGE) shares fell 5.78% after announcing Phase 2 Huntington's Disease study results, which met primary endpoints but led to price target adjustments by analysts.
June 11, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Sage Therapeutics shares dropped 5.78% after announcing Phase 2 Huntington's Disease study results. The study met its primary endpoint, but analysts adjusted their price targets, maintaining neutral and hold ratings.
The announcement of the Phase 2 study results, despite meeting primary endpoints, led to a significant drop in share price. Analysts' neutral and hold ratings with adjusted price targets indicate cautious sentiment, contributing to the negative short-term impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100